Navigation Links
Global menopause summit concludes HRT is safe for healthy women entering menopause
Date:5/19/2008

Global menopause summit concludes HRT is safe for healthy women entering the menopause.

HRT in the early postmenopausal period is safe, and healthy women going through the first few years of the menopause who need HRT to relieve symptoms should have no fears about its use. This is the conclusion and clinical advice of the First Global Summit on Menopause-Related Issues, which was held in Zrich on March 29th and 30th, 2008.

The Zrich Summit was attended by global experts in menopause and related issues. It reviewed the evidence on the safety, risks and benefits of HRT in the first few years of the menopause, looking at 4 main areas of controversy: cardiovascular health, breast issues, cognition, and bone issues. Summit members compared public perception with actual safety, and are now issuing a state-of-the science summary, to enable women and clinicians to make informed judgements about whether or not to use HRT in early menopause.

Professor Amos Pines, President of the International Menopause Society, will present the Summit findings at the World Congress on the Menopause in Madrid on 20th May.

Background the WHI Study

Hormone replacement therapy (HRT) use declined after the Womens Health Initiative (WHI) study results were published in 2002. Initial results from the WHI study seemed to show that women taking HRT were at greater risk of breast cancer and heart disease, and this study had a dramatic effect on public perceptions and confidence in the use of HRT. However, since the first WHI information was released, it has become apparent that the study group was not completely representative of women taking HRT, and was characterized by a high incidence of several important risk factors, unusual in younger women around their menopause. For example:

  • The average age of women in the WHI study was 63 years of age, which is a decade older than the age at which most women begin taking HRT

    '/>"/>


Contact: Tom Parkhill
trparkhll@yahoo.co.uk
44-750-921-5465
International Menopause Society
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses
2. Chiltern Expands Its Global Reach to Latin America
3. Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes
5. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare Conference
7. MEDEX Global Group Acquires ASI Group
8. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
9. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
10. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
11. AUA 2008: Global warming may lead to increase in kidney stones disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...MDS Inc. (TSX: MDS; NYSE: MDZ ), a leading provi...iences markets, today reported its final fourth-qu...-end audit for the period ended October 31, 2008. ... 2008, MDS reported total revenue of $322 million....ll write-down, previously estimated to be in the r...
(Date:1/8/2009)...tCall/ -- Cardinal Health today,announced it expe...ts for its,fiscal second quarter, but provided ca...e of a deferral in hospital capital spending affec..., Non-GAAP diluted EPS from continuing opera... ended Dec. 31, 2008, is anticipated to be at leas...
(Date:1/8/2009)...come Organ Donors and Provide the Gift of Life , ...ff Timmons, the founder of the pop band 98 Degrees... all of his fans - sign up today to become organ d... http://www.newscom.com/cgi-bin/prnh/20090108/NY56... the newly formed Heather Trew Foundation, Timmons...
(Date:1/8/2009)...Call/ -- Elsevier, the leading,publisher of medic... it,renewed its publishing partnership with the A...acc.org ), the leading nonprofit medical society i...ment calls for Elsevier to publish,the society,s ...of Cardiology,(JACC) ( http://www.elsevier.com/l...
Breaking Medicine News(10 mins):Health News:MDS Reports Final Fourth-Quarter 2008 Results 2Health News:MDS Reports Final Fourth-Quarter 2008 Results 3Health News:MDS Reports Final Fourth-Quarter 2008 Results 4Health News:Cardinal Health Updates FY09 Outlook 2Health News:Cardinal Health Updates FY09 Outlook 3Health News:Cardinal Health Updates FY09 Outlook 4Health News:Cardinal Health Updates FY09 Outlook 5Health News:Jeff Timmons and the Heather Trew Foundation Join Forces to Promote Organ Donations 2Health News:The American College of Cardiology Renews its Publishing Partnership With Elsevier 2Health News:The American College of Cardiology Renews its Publishing Partnership With Elsevier 3
...ondon: Breast Cancer is the most notorious of canc...ntly, of all the cancers diagnosed in women//, one...The present modern day living is being blamed for ...present record for breast cancer is 36,939 cases i...
...s part of its continued efforts to give back to th...its annual scientific meetings//, the Fairfax, Vir...logy and Oncology (ASTRO) is partnering with Cance...vivorship. The Cancer Hope Network is a non-profit...
...ransfer of a gene that produces a mutant form of g...-plaque and anti-inflammation benefits than therap...use study conducted by cardiology researchers at C...d in the Oct. 3 issue of the Journal of the Americ...
...MR shots found itself in the eye of a storm in the...to autism in some cases.// Recent statistics enabl...irmed their faith in the MMR shots, and are well o...from Measles, Mumps and Rubella. The number of MM...
Other Medicine News:Health News:Cancer Hope Network, ASTRO Partner to Raise Awareness of Cancer Survivorship 2Health News:Gene Transfer Using Mutant Form of Good Cholesterol Cuts Vascular Plaque and Inflammation 2Health News:Gene Transfer Using Mutant Form of Good Cholesterol Cuts Vascular Plaque and Inflammation 3
(Date:1/7/2009)...ire-FirstCall/ -- Eli Lilly and Company,(NYSE: ...response letter from,the U.S. Food and Drug Admin...ion (LAI) for acute and maintenance treatment of s...rk with the agency on the new drug,application (N...nal clinical trials for the continued,review of t...
(Date:1/7/2009)...e/ -- ImQuest Life Sciences announced today the su...ood and Drug Administration to initiate human clin...ibitor IQP-0410. ImQuest anticipates initiating th...IQP-0410 is a novel small molecule inhibitor of HI...transcriptase inhibitor (NNRTI). The compound poss...
(Date:1/7/2009)...RNewswire/ -- Circassia Ltd, a specialty,biopharm...care, today,announced that following successful c...une(R) anti-allergy technology, the company has no...se II clinical trial in cat allergy. The,study, w...ents with confirmed,cat allergies, and all the pa...
(Date:1/6/2009).../ -- In recent controlled studies conducted by Dr....sts found that the patented ingredient in Glyc,n G...ingredient to increase levels of nitric oxide (NO)...rate (NOx) in human subjects. , , Nitric oxide ...lood flow to the skeletal muscles. This is signif...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Environmental Tectonics Corporation Announces Sale of Two Hyperbaric Monoplace Chambers 19708 1Environmental Tectonics Corporation Announces Sale of Two Hyperbaric Monoplace Chambers 19708 2Environmental Tectonics Corporation Announces Sale of Two Hyperbaric Monoplace Chambers 19708 3Environmental Tectonics Corporation Announces Sale of Two Hyperbaric Monoplace Chambers 19708 4Direct Medical Systems Reaches Profitability in 2 1 2 Years as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System the InNovaSou 5495 1Direct Medical Systems Reaches Profitability in 2 1 2 Years as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System the InNovaSou 5495 2RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2111 1RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2111 2RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2111 3RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2111 4RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2111 5RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2111 6Drug brings relief for many IBS patients who experience constipation 19697 1Drug brings relief for many IBS patients who experience constipation 19697 2
..., 2007 - Synthetic Blood,International, Inc. (OTCB...stical analysis of its Phase IIa study with Oxycyt...line with preliminary,study results announced in D...he primary endpoint of increasing patients, oxygen...ta also show a,decrease in patient glucose and lac...
...ast 45% additional,reduction in patients, LDL-chol...wering therapies, CARLSBAD, Calif., May 17, 2007 /.... announced updated results from its ongoing,Phase...homozygous,familial hypercholesterolemia (HoFH), i... the of Cardiology Annual Scientific Session,(ACC)...
Other Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5
...mera systems for qualified microscopic documentati...ith images of highest color fidelity, resolution a...s can rely on access to perfect images due to the ...nnovative readout modes make this camera the best ...
The U-III's compact, sleek design and advanced exposure system with multi-point sensor, make it the system of choice for serious fluorescence applications including FISH. It is ideal for use at resea
The DS-5M-L1 consists of a 5-megapixel color matrix CCD for high resolution and breathtaking colors, camera control unit with a full range of features, including a crystal clear LCD display monitor.
This compact photomicrographic system assures simple operation to achieve the exposure accuracy required for sophisticated photomicrography in most research and clinical environments.
Medicine Products: